APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06687070
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 464
- Registration Number
- NCT06641414
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Study of Olverembatinib in SDH-deficient GIST.
- First Posted Date
- 2024-10-14
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06640361
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of Olverembatinib (HQP1351) in Patients With CP-CML
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT06423911
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 486
- Registration Number
- NCT06389292
- Locations
- 🇨🇳
Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT06319456
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Study of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus.
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06182969
- Locations
- 🇨🇳
Renji Hospital Shanghai Jiaotong University School of Medical, Shanghai, Shanghai, China
Global Trial in APG2575 for Patients With CLL/SLL
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06104566
- Locations
- 🇷🇺
Kaluga Regional Clinical Research, Kaluga, Russian Federation
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT06051409
- Locations
- 🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Alfred Health, Melbourne, Victoria, Australia
A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT05773586
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China